Praluent Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to rising prevalence of hypercholesterolemia, limitations of statin-only therapies, increased cardiovascular risk screening, expansion of biologic cardiovascular drugs, growing specialist cardiology care.

The growth in the forecast period can be attributed to rising focus on aggressive lipid lowering strategies, increasing adoption in secondary prevention, expansion of value-based cardiovascular care, growing payer support for pcsk9 inhibitors, increasing awareness of cardiovascular risk reduction. Major trends in the forecast period include increasing use of pcsk9 inhibitors in lipid management, rising adoption in high-risk cardiovascular patients, growing integration with statin combination therapy, expansion of preventive cardiology programs, enhanced focus on long-term ldl control.

The growing prevalence of obesity is expected to drive the expansion of the Praluent market in the future. Obesity is a medical condition marked by excessive body fat accumulation, which poses health risks, and is generally defined by a Body Mass Index (BMI) of 30 or higher. The rise in obesity is primarily linked to changes in global food systems and eating behaviors, such as increased consumption of ultra-processed foods, sedentary lifestyles, and economic factors that make unhealthy food options more accessible. Praluent addresses obesity by lowering LDL cholesterol levels in individuals with obesity-related dyslipidemia. As a PCSK9 inhibitor, it enhances the liver's ability to clear LDL cholesterol from the bloodstream, thereby improving cardiovascular health and reducing obesity-related complications. For example, in May 2024, a report from the Office for Health Improvement and Disparities, a UK-based government agency, estimated that 64% of adults (18+) in England were either overweight or living with obesity during the 2022-2023 period, with 26.2% of the population being classified as obese (BMI ≥ 30 kg/m²). Consequently, the rise in obesity is expected to drive the growth of the Praluent market.

The increasing adoption of personalized medicine is expected to further propel the growth of the Praluent market. Personalized medicine is an approach where clinicians tailor treatments to an individual’s biological characteristics to improve clinical outcomes. The rising preference for personalized medicine stems from clinicians' increasing desire for therapies that align with genetic and biomarker profiles, allowing for more precise treatment. Praluent facilitates the growing adoption of personalized medicine, as its targeted PCSK9-inhibiting mechanism enables clinicians to tailor LDL-cholesterol reduction based on individual cardiovascular risk profiles. For instance, in February 2025, BioSpace, Inc., a U.S.-based life science news platform, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. As a result, the increasing adoption of personalized medicine is anticipated to drive further growth in the Praluent market.

Major companies in the Praluent market are concentrating on developing innovative solutions, such as therapies for lowering low-density lipoprotein cholesterol (LDL-C), to address the growing demand for advanced cardiovascular risk-reduction treatments. LDL-C-lowering therapies are specialized interventions designed to significantly reduce levels of "bad cholesterol," providing more precise, targeted, and sustained lipid control than traditional statins or lifestyle changes alone. For example, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received extended approval from the U.S. Food and Drug Administration (FDA) for Praluent (alirocumab) injection, an advanced biologic LDL-C-lowering therapy. This updated approval allows its use as an adjunct to diet and existing lipid-lowering treatments for pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). Praluent is a PCSK9 inhibitor monoclonal antibody that enhances LDL receptor availability, leading to significant and sustained LDL-C reduction. The therapy offers high efficacy, favorable safety, and less frequent dosing compared to many traditional lipid-lowering therapies. By expanding access to children with genetic high cholesterol, Praluent helps manage early-onset cardiovascular risk and promotes long-term heart health.

Major companies operating in the praluent market are Sanofi S.A., Regeneron Pharmaceuticals Inc.

North America was the largest region in the praluent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the praluent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the praluent market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the praluent market by increasing costs of imported monoclonal antibody raw materials, bioreactor equipment, purification systems, prefilled syringe components, and cold-chain distribution services. North America and Europe are most affected due to dependence on international biologics manufacturing inputs, while Asia-Pacific faces pricing pressure on export-oriented production. These tariffs contribute to higher biologic therapy costs and reimbursement scrutiny. However, they are also encouraging domestic antibody manufacturing, regional supply chain optimization, and increased investment in local biologics infrastructure.

The praluent market research report is one of a series of new reports that provides praluent market statistics, including praluent industry global market size, regional shares, competitors with a praluent market share, detailed praluent market segments, market trends and opportunities, and any further data you may need to thrive in the praluent industry. This praluent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Praluent is a monoclonal antibody used to manage high cholesterol, particularly low-density lipoprotein (LDL) cholesterol, often referred to as bad cholesterol. It is indicated for treating adults with primary hypercholesterolemia or mixed dyslipidemia, as well as for reducing cardiovascular risk in patients with established heart disease.

The primary indications for Praluent include primary hypercholesterolemia, mixed dyslipidemia, and established atherosclerotic cardiovascular disease (ASCVD). Primary hypercholesterolemia is a hereditary condition characterized by high LDL cholesterol levels in the blood. Praluent, which contains alirocumab, targets and blocks the PCSK9 protein, thereby lowering LDL cholesterol levels. It is available through various distribution channels, including hospitals, clinics, retail pharmacies, and specialty pharmacies, and is used by a range of end users, such as ambulatory care settings and homecare.

The praluent market consists of sales of praluent (alirocumab) injection and one per-filled pen. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.